^
    Back
    Association details:
    Biomarker:BRCA1 mutation
    Cancer:HER2 Negative Breast Cancer
    Drug Class:PARP inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    ESMO.org
    Title:

    ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer

    Excerpt:
    Recommendations...Patients who may be considered for treatment with a PARP inhibitor should be offered genetic testing for pathogenic variants in BRCA1 and BRCA2 regardless of age, family history or breast cancer subtype...
    DOI:
    https://doi.org/10.1016/j.annonc.2021.09.019.
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2023
    Title:

    Neoadjuvant PARP inhibitors in patients with early HER2-negative breast cancer harboring BRCA 1/2 germline mutations: A systematic review and meta-analysis.

    Published date:
    05/25/2023
    Excerpt:
    ...we explore the efficacy and safety of neoadjuvant PARPi in early HER2-negative BC patients....In a pooled analysis, gBRCAm carriers achieved a significantly higher rate of pCR than BRCA wild-type patients (56% versus 37%, p=0.04) with neoadjuvant PARPi….The addition of PARPi in the neoadjuvant setting improves pCR in early-stage HER2-negative breast cancer and germline BRCA 1/2 mutations
    DOI:
    10.1200/JCO.2023.41.16_suppl.e12611
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    SABCS 2020
    Title:

    Patient reported outcomes (PROs) with poly(ADP-ribose) polymerase inhibitors (PARPi) versus chemotherapy (CTX) in patients (pts) with germline BRCA1/2 mutated (gBRCA1/2mut) HER2- advanced breast cancer (ABC): Results from a multi-country real-world (RW) study

    Published date:
    11/17/2020
    Excerpt:
    PARPi have demonstrated superior efficacy and favorable PROs vs. CTX in RCTs in pts with gBRCA1/2mut HER2- ABC.